Titre : | Cost study of the clinical management of prostate cancer in France: results on the basis of population-based data. |
Titre original: | Etude du coût de la prise en charge clinique du cancer de la prostate en France : résultats basés sur des données en population générale. |
Auteurs : | L. MOLINIER ; C. CASTELLI ; E. BAUVIN |
Type de document : | Article |
Dans : | EUROPEAN JOURNAL OF HEALTH ECONOMICS (THE) (12 Num 4, 01/08/2011) |
Article en page(s) : | 363-371, tabl., fig. |
Note générale : | Référence : 41 réf. |
Langues: | Anglais |
Catégories : |
[BDSP5] Anatomie > Appareil urogénital > Appareil génital > Appareil génital mâle > Prostate [BDSP5] Economie santé > Coût santé > Coût maladie [BDSP5] Géographie > Géographie humaine > Région > Département [BDSP5] Géographie politique > Monde > Europe > France [BDSP5] Information & communication [NI] > Information > Nature information [NI] > Donnée statistique [BDSP5] Information épidémiologique > Recueil données > Registre > Registre maladie [BDSP5] Pathologie > Tumeur > Cancer [BDSP5] Pratique médicale > Recherche médicale > Epidémiologie [BDSP5] Thérapeutique > Radiothérapie |
Résumé : | Prostate cancer is an important disease in terms of economic implications because of its increasing incidence and health care costs. We assessed the direct costs of the clinical management of prostate cancer in France. A retrospective study based on population-based data was carried out. Eight hundred and seventy-nine cases of prostate cancer diagnosed in five departments were included in a 5-year follow-up study. The economic analysis adopted the healthcare payer?s perspective and took into account only the direct costs. The mean cost of managing patients was estimated at ?12,731. It is composed of 49 to 82% of initial treatments according to the therapeutic strategy. The follow-up constituted between 3 and 11%, the costs of treatments for side effects between 1 and 3% and the travel cost between 3 and 7%. Cumulative total costs over 5 years for each treatment group showed variation in costs. Costs were highest for patients who were treated with external-beam radiotherapy and lowest for those with watchful waiting. The cost burden of prostate cancer is high and varies according to the treatment type. This study yielded a cost analysis of the different management practices of patients with prostate cancer. |
Exemplaires (1)
Code-barres | Cote | Support | Localisation | Section | Disponibilité |
---|---|---|---|---|---|
0060129 | P151 | Article | Documentation IRDES | P : périodiques | Disponible |